In this photo illustration, the Amicus Therapeutics logo is displayed on the screen of a tablet.
Sheldon Cooper | Lightrocket | Getty Images
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock’s last close.
With this deal BioMarin gains access to Amicus’ treatments for genetic disorders Fabry disease and Pompe disease.
BioMarin expects to finance the deal with cash and $3.7 billion debt.
The acquisition will add revenue immediately after the transaction closes, BioMarin said.
The deal is expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
About The Author
